Noroviruses in children seen in a hospital for acute gastroenteritis in Finland by Räsänen, Sirpa et al.
ORIGINAL PAPER
Noroviruses in children seen in a hospital for acute
gastroenteritis in Finland
Sirpa Räsänen & Suvi Lappalainen & Marjo Salminen &
Leena Huhti & Timo Vesikari
Received: 8 December 2010 /Accepted: 1 March 2011 /Published online: 5 April 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Noroviruses (NoVs) are second only to rotaviruses
(RVs) as causative agents of acute gastroenteritis (AGE) in
children. The proportional role of NoVs is likely to increase
after control of RV by vaccination. We investigated NoVs in
children seen in Tampere University Hospital either treated as
outpatients or hospitalized because of AGE before universal
RVvaccinationwasimplementedinFinland.Thisprospective
studywasconductedfromSeptember2006toAugust2008.A
total of 1,128 children <15 years of age with symptoms of
AGE were enrolled either in the hospital clinic or in a ward,
and stool samples for NoV studies were obtained from 759
children. NoVs were found in 196 (26%) cases. In the first
year, NoVs were found in 116 (34%) out of 341, and in the
second year, in 80 (19%) out of 418 cases. RVs were found
respectively in 128 (38%) and 260 (62%) cases in these two
seasons. Both RV and NoV were present in 24 cases. NoV
genotype GII.4 predominated with a 96% share of the NoV
cases in the first season and an 80% share in the second
season. Other NoV genotypes seen infrequently were GII.7,
GIIb, GI.6, GII.1, GII.2, and GIIc. The median clinical
severity of NoVAGE was 14 compared to 16 for RVAGE on
a 20-point scale. Conclusion: NoVs were nearly as common
as RVs as causative agents of severe AGE in children seen in
hospital. After implementing universal RV vaccination, the
importance of NoVs will still increase further.
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Introduction
Noroviruses (NoVs) are major causative agents of acute
gastroenteritis (AGE) in outbreaks in children and adults
[1, 9–11]. In children, NoVs are also a common cause of
s e a s o n a lA G E ,a sd e s c r i b e di nF i n l a n di nas t u d yi n1 9 9 3 –
1995 [15, 16]a n dl a t e re l s e w h e r e[ 4, 9, 10, 24]. In
hospital-based studies of seasonal AGE in children, the
incidence of NoVs has been lower than that of RVs [9, 14,
15, 17, 26, 27], but particularly in community-based
studies, NoVs have been the second most common, or
sometimes even the most common causative agents of
AGE in children [3, 5, 7, 10, 16–18]. Considering both
frequency and severity, NoVs are the second most
important cause of viral AGE in children [9, 16, 17, 26],
and their importance will be further underscored following
universal RV vaccination.
NoVs belong to human caliciviruses (HuCVs), which are
divided into NoVs and sapoviruses (SaVs). Seasonal NoV
AGE in children is most often caused by genogroup GII
NoVs, and both GI and GII are seen in outbreaks. Since the
mid 1990s, genotype GII.4 has emerged and become the
predominant NoV type in outbreaks [23]. The emergence of
GII.4 has also resulted in an overall increase of NoV
outbreaks [14]. GII.4 is also the dominant strain detected in
seasonal NoVAGE [23], which may have led to an increase
of NoVAGE in children in general. The reason may be the
greater virulence of GII.4 compared to other NoV geno-
types [13, 28].
In this study, we investigated the occurrence and types of
NoVs in children seen in Tampere University Hospital
either as outpatients or admitted to a ward because of AGE.
We also assessed the severity of NoV AGE in comparison
to RV AGE.
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Clinical methods
This prospective study was conducted in Tampere Univer-
sity Hospital in September 2006–August 2008. The hospital
is the pediatric referral center for the Pirkanmaa Hospital
District, a mainly urban area with a child population of
about 79,000. The study protocol was approved by the
Ethics Committee of Pirkanmaa Hospital District.
All children ≤15 years of age treated in the emergency
room (ER), or admitted to the hospital ward for AGE, or
caught nosocomial AGE while hospitalized for another
reason in Tampere University Hospital, were eligible for
enrolment. The diagnosis of AGE was made by a doctor in
the hospital. The AGE was considered to be nosocomial if
the symptoms began at least 24 h after hospitalization. Prior
to enrolment, a parent or legal guardian was informed about
the study and signed an informed consent form.
If the child had more than one ER visit or hospitalization
during the study period, we deemed the AGE symptoms to
belong to the same episode if there were fewer than seven
symptom-free intervening days. Otherwise the visits were
considered to represent two separate episodes.
At enrollment, the parents were interviewed about the
child’s AGE symptoms and treatment before the hospital
visit, and their rotavirus vaccination status was ascertained.
A questionnaire about the total duration of the symptoms
after discharge was requested to be completed and returned
after recovery. After discharge from the ER or the hospital
ward, additional clinical information and possible laborato-
ry test results of the AGE episode were collected from the
medical records. A stool sample was collected while in the
hospital. We failed to collect the sample if the child did not
pass stools while in the hospital. If the parents did not
return the questionnaire, the duration of symptoms at home
remained unknown. Severity of the AGE episode was
assessed using a 20-point score [19], in which ≥11 points is
usually considered to be severe AGE. This score considers
the following symptoms and features: fever, duration and
intensity of diarrhea, duration and intensity of vomiting,
degree of dehydration and treatment given, and need for
hospitalization. If information on one or more of these
items was missing, the case was excluded from the severity
analysis. The statistical analyses were done using SPSS
15.0 with Mann–Whitney and Kruskal–Wallis tests.
Apart from the prospective surveillance, we also collect-
ed discharge information on all patients ≤15 years of age
treated for AGE in Tampere University Hospital during the
study period. For this purpose, all the ICD-10 diagnoses of
groups A01–A09 were retrieved.
In the second follow-up season, an extensive water-
borne AGE outbreak occurred in Nokia, a town close to
Tampere. The outbreak was caused by massive contam-
ination of drinking water by sewage water and caused
extraordinary severe and mixed AGE [12, 21]. Because of
the uncommon features associated with the AGE cases in
this outbreak, we excluded the cases associated to this
outbreak from this analysis; the cases have, however, been
reported separately [19].
Laboratory methods
All stool samples were studied by reverse transcription
(RT)-PCR for HuCVs and RVs. HuCVs were detected
using a modified RT-PCR method introduced by Jiang and
Farkas [2, 8]. These primers, localized in the RNA
polymerase region, co-detect NoVs and SaVs: in this study,
we describe the NoV findings. All PCR-positive amplicons
were sequenced to confirm the PCR results and to
determine the NoV genotype. Original genotypes for
validation have been described earlier [2, 8]. We used
NoV GI.1, GI.3, GI.4, GI.6, GII.1, GII.2, and GII.4
genotypes for PCR validation. In addition, we have later
found other genotypes using this same PCR, such as GIIb,
GII.7, GI.2, GII.9, GIIU, and GIId [6]. RV G types were
determined by RT-PCR as described by Pang et al. [16]
with the Taq polymerase replaced by GoTaq® polymerase
(Promega, Madison, WI, USA). Both RT-PCR methods are
highly sensitive detecting viruses and can be made from the
smallest amount of sample as well as from diapers.
Negative findings do not need confirming tests. If there
was any uncertainty in the positive findings or sequencing,
the tests were repeated.
The presence of RV antigen in stools was detected with
ELISA using IDEIA
® Rotavirus kit (Oxoid Ltd., UK)
according to the manufacturer’s protocol. The ELISA test is
not as sensitive as the PCR techniques and cannot be
performed from diapers.
Results
A total of 1,723 patients ≤15 years of age presented with
AGE in the Tampere University Hospital during the study
period. The number of patients recruited was 1,193, of
whom 65 were excluded because of association with the
waterborne AGE outbreak in Nokia [20], and thus, 1,128
(65% of the total cases of AGE) were included in this study.
Among these, there were 45 (4%) children, who were
known to have received at least one dose of either of the
RV vaccines. Stool samples were obtained from 759
children (67% of included and 44% of all eligible)—341
in the first AGE season (September 2006–August 2007)
and 418 in the second season (September 2007–August
2008).
1414 Eur J Pediatr (2011) 170:1413–1418The cases of AGE positive for HuCV and RV are
shown in Table 1. In the first season, 116 out of 341
(34%) and, in the second season, 80 out of 418 (19%)
AGE cases were positive for NoV, and in both seasons
combined 196 of all 759 (26%). Of the NoV-positive
cases, 24 (12%) were mixed infections with RV. In the first
season, 4 (1%) out of 341 stools and, in the second season,
8 out of 418 (2%) stools were positive for SaV; of these, 2
were mixed infections with RV. There were no cases with
both NoV and SaV or more than one type of NoV in the
stools at the same time. No child had more than one
episode of NoV AGE during the follow-up. RVs were
present in 128 (38%) AGE cases in the first, and 260
(62%) in the second follow-up season, of which 26 (7%)
were mixed infections with a NoV or SaV. RV was found
in seven specimens from the children who were known to
have received RV vaccines; of these, three were vaccine-
type viruses from recent vaccination.
Genotype GII.4 was the predominant NoV genotype
detected in both seasons. In the first season, 111 (96%) and,
in the second season, 64 (80%) of the NoV-positive cases
were of genotype GII.4 (Table 2).
The age range of the children treated because of NoV
AGE was from 19 days to 13 years 8 months. The median
age was 15 months, and the peak incidence was between 6
and 18 months of age. Altogether, 72% of children were
≤24 months of age. In the children treated because of SaV
AGE, the age ranged from 6 months to 2 years 10 months,
the median being 22 months (Fig. 1).
A clear seasonality was seen in NoVAGE in both years.
The most active NoV period in the first season was from
February to April 2007 and in the second season from
January to April 2008 (Fig. 2). The SaV AGE cases were
scattered with no obvious seasonality.
Of the AGE cases that had NoV as the only causative
agent, 80 out of 172 (47%) were admitted to the hospital
and 81 (47%) were treated as outpatients. The remaining 11
cases (6%) were nosocomially acquired. For comparison, of
the 362 AGE cases with a RV as a single causative agent,
189 (52%) were admitted to the hospital, 161 (44%) were
treated as outpatients, and 12 (3%) were nosocomial. Of the
children admitted to the hospital because of AGE, NoV was
the causative agent in 21% and RV in 50% of the cases.
Of the 369 cases from which the stool sample could not
be obtained, 298 (81%) were treated as outpatients, 64
(17%) were admitted to a ward, and 7 (2%) were
nosocomially acquired AGE. We enrolled 48 cases of
nosocomially acquired AGE and obtained stool samples
from 41 of these. In 11 (27%) of these, the causative agent
was NoV, in 12 (29%) the causative agent was RV, and in 4
(10%) both NoVand RV were found. No SaVs were found
in nosocomial AGE.
Clinical severity score could be calculated in 79 out of
171 (46%) of NoV-positive and RV-negative, and 196 out
of 356 (55%) RV-positive and NoV-negative AGE cases.
The severity scores of AGE cases caused by NoV ranged
from 8 to 19, and cases caused by RV from 10 to 20
(Fig. 3). Median severity of AGE cases with a NoV as
single causative agent was 14, and with a RV as a single
causative agent, median was 16. The difference between the
Table 1 Causative agents of acute gastroenteritis in children seen in
Tampere University Hospital in September 2006–August 2008
Virus 1st season (%) 2nd season (%) Total (%)
Norovirus (NoV) 105 (31) 67 (16) 172 (23)
Sapovirus (SaV) 4 (<1) 6 (1) 10 (1)
Rotavirus (RV) 117 (34) 245 (59) 362 (48)
Mixed NoV + RV 11 (3) 13 (3) 24 (3)
Mixed SaV + RV 0 (0) 2 (<1) 2 (<1)
Other/undefined 104 (30) 85 (20) 189 (25)
Total 341 (100) 418 (100) 759 (100)
Table 2 Norovirus genotypes seen in acute gastroenteritis in children
in two seasons (September 2006–August 2008) in Tampere University
Hospital
Genotype 1st season (%) 2nd season (%) Total (%)
GII.4 111 (96) 64 (80) 175 (89)
GII.7 1 (<1) 4 (5) 5 (2)
GIIb 0 (0) 11 (14) 11 (6)
GII.1 2 (2) 0 (0) 2 (1)
GIIc 1 (<1) 0 (0) 1 (<1)
GI.6 1 (<1) 0 (0) 1 (<1)
GII.2 0 (0) 1 (1) 1 (<1)
Total 116 (100) 80 (100) 196 (100)
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Fig. 1 Age distribution of children seen in Tampere University
Hospital because of norovirus and sapovirus gastroenteritis in
September 2006–August 2008
Eur J Pediatr (2011) 170:1413–1418 1415severities of AGE caused by NoV and RV was statistically
significant (P<0.01).
Discussion
This study confirmed both the prevalence and clinical
importance of NoVs as the causative agent of seasonal
AGE in children. At the hospital level, NoVs are, after RVs,
the second most important causative agents of AGE in
children admitted to a hospital or treated as outpatients. In
some seasons, they may be as important as RVs, being as
frequent as RV AGE, which was the situation in the first
season, resulting in significantly severe cases of AGE.
Overall, the 26% proportion of NoVs in the total material
and the 21% proportion among children hospitalized with
AGE appear higher than generally reported in the past. For
example, in a review of published studies from 1990 to
2008, Patel et al. counted that the pooled proportion of
NoVs was 11% [17]. We propose that the proportional
increase may also reflect an absolute increase of NoVAGE
in children, possibly due to greater virulence of the recently
emerged genotype GII.4.
Of the 1,723 eligible children, 1,193 were recruited. The
rest were lost mainly because of the ER being too busy to
be able to recruit all the eligible cases. Sixty-five cases
belonging to the AGE outbreak in Nokia were excluded
from this analysis because of the extraordinary features of
this outbreak leaving 1,128 cases in this study material.
Furthermore, stool samples could be obtained only from
759 of the 1,128 enrolled children because the stools were
collected only in the hospital. There were many children
who spent only a few hours in the ER passing no stools
during that time. A possibility of a bias in the AGE-causing
agents resulting from these matters cannot be totally
excluded, and the majority of stool samples are from the
severe AGE cases. However, we could see no relation
between the causative agent and passing stools in the ER.
Even with these limitations, our study represents almost
half (47%) of all the AGE cases seen in the hospital in
children in the 2-year period.
NoV AGE showed seasonality with activity peaking in
wintertime and only little NoV activity in the summer
months. This confirms that NoVs are not involved only in
outbreaks, but are also important causative agents in
seasonal epidemic AGE. Like RVs, NoVs have winter
seasonality, but in this study the seasons were distinct, with
NoVs occurring earlier than RVs.
In the first follow-up year, from September 2006 to
August 2007, RVactivity was unusually low and associated
with several RV G types. By contrast, RV activity in the
second year from September 2007 to August 2008 was high
and associated with the most common RV G-type G1P [8].
In the circumstances of low RV activity in the first season,
the NoVs caused as many AGE hospitalizations as RVs, but
when RV activity was high, the proportion of NoV AGE
cases seen in the hospital was lower. Furthermore, the
“virulent” NoV genotype GII.4 predominated particularly
in the first season with a 96% share. It is tempting to
speculate that simultaneous occurrence of the high NoV
activity with the virulent GII.4 genotype and the low RV
activity with multiple G types may be more than a
coincidence. In any case, while RV G1P [8] re-emerged
as the dominant RV type in the second season of follow-up,
the NoVactivity decreased, the proportion of GII.4 became
less, and other NoV types appeared.
In general, NoV GII.4 has been the most common
NoV strain detected in children, as well as in adults, this
century. GII.4 activity varies from one season to another
[22, 23, 28]. Such variation may be associated with
mutations in the antigenic epitopes or other parts of the
NoV genome [25, 28].
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Fig. 3 Severity of clinical symptoms of acute gastroenteritis caused
either by norovirus (n=79) or rotavirus (n=196) (September 2006–
August 2008). Severity is assessed with a 20-point scale in which ≥11
points is considered as severe
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Fig. 2 Seasonality of the noroviruses seen in acute gastroenteritis in
children (September 2006–August 2008) in Tampere University
Hospital
1416 Eur J Pediatr (2011) 170:1413–1418SaVs were not the point of primary interest in this study
and are not discussed at length. SaV findings were single
cases scattered throughout the follow-up: 12 cases were
seen, of which 2 (17%) were mixed AGE cases with RV.
We supposedly did not obtain information about all the
nosocomially acquired AGE in the hospital in the study
period. If the child is hospitalized for another reason and
gets AGE symptoms, he/she is usually discharged as soon
as possible, and unfortunately, often no ICD-10 diagnosis
of AGE is recorded. Nosocomial AGE is not discussed in-
depth here because its real incidence is probably higher
than what is seen in this study.
Weusedthe20-pointseverityscale toassesstheseverityof
those AGE episodes which were not associated with the
Nokia AGE outbreak of November–December 2007. The
severity of NoV cases seen in the hospital was somewhat
lower than that of RV cases (Fig. 3). However, the median
severities of the AGE cases caused either by NoV, RV, or both
were over 11, which is considered severe. If we assess the
severity of AGE using only the hospitalization rate among the
children, NoVAGE cases seem almost as severe as RV cases:
of the NoVAGE cases, 47% were hospitalized and 47% were
treated as outpatients; of the RV AGE cases, 54% were
hospitalizedand42% weretreated asoutpatients.The number
of non-GII.4 types seen was small and did not permit
statistical comparison of clinical severity between GII.4 and
other NoV genotypes. Median severity of the AGE caused by
GII.4 NoV was 14 (n=71) with a range from 8 to 19.
Presumably, the overall high severity of the AGE cases in
our study was reflected in the hospital-based study design and
in the fact that we did not obtain stool samples for analysis
frommany of the cases not needing hospitalization.However,
the NoV AGE cases seen in this study were unexpectedly
severe, even in a hospital setting. This may be a sign of the
proposed greater severity of genotype GII.4 NoVs compared
to the other genotypes. The omission of such cases may
influence the assessment of mean clinical severity of AGE
associated with NoVor other gastroenteritis viruses.
There are only a few prospective follow-up studies on
both endemic circulating NoV genotypes and severity of
endemic NoV AGE in children. The results of this survey
also serve as a baseline to subsequent studies of AGE in
children to be conducted after the introduction of universal
RV vaccination in Finland in September 2009. It is
expected that the proportional role of NoV will increase
along with a decrease in RVs. It will be of particular interest
to see if the absolute numbers of NoVAGE also increase in
the future.
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